RxDoctor Payments DataLook up a doctor →

Ramin Sarrafizadeh, MD

Retina Specialist · Colorado Springs, CONPI 1700813391

Payments from drug & device makers

$1,672,770in general payments, 2019–2025

Across 151 payments — averaging $11,078 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1.2M
  • Ocular Therapeutix, Inc.$403K
  • Eyepoint US, Inc.$19K
  • ANI Pharmaceuticals, Inc.$19K
  • Novartis$10K
  • US Retina LLC$6K
  • plus $296 from 5 others
$36,982in research payments, 2019–2025

Across 10 payments — averaging $3698.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alimera Sciences, Inc.$27K
  • Ocular Therapeutix, Inc.$10K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,672,770 in reported general payments places this provider in the 90th percentile of 51 retina specialist providers in Colorado.

See all retina specialist providers in Colorado

Medicare billing

Part B allowed, 2024
$5,962,226
Medicare patients
666
Services billed
70,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other retina specialist in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →